-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The US Food and Drug Administration approved the second oral drug that can be used urgently to treat new coronavirus infections on the 23rd
.
.
The U.
S.
Drug Administration said in a statement that the oral drug produced by Merck in the United States is called monabiravir, which is used to treat adults with mild to moderate new coronary disease and people with a higher risk of severe illness.
And people who cannot use other treatment programs approved by the US Drug Administration
.
S.
Drug Administration said in a statement that the oral drug produced by Merck in the United States is called monabiravir, which is used to treat adults with mild to moderate new coronary disease and people with a higher risk of severe illness.
And people who cannot use other treatment programs approved by the US Drug Administration
.
The statement said that monabigravir is a prescription drug, and patients must take it as soon as possible after the diagnosis of the new crown, and start taking it within 5 days after the appearance of the new crown symptoms, and the continuous use time cannot exceed 5 days
.
.
The statement said that monabiravir should not be used in people under the age of 18 because the drug may affect bone and cartilage growth
.
According to the results of animal reproduction studies, monabiravir is not recommended for women during pregnancy
.
Common side effects of this drug may include diarrhea, nausea, and dizziness
.
.
According to the results of animal reproduction studies, monabiravir is not recommended for women during pregnancy
.
Common side effects of this drug may include diarrhea, nausea, and dizziness
.
Cavazzoni, director of the Center for Drug Evaluation and Research of the U.
S.
Drug Administration, said that with the continuous emergence of new mutant strains, it is critical to expand the available programs for the treatment of new crown infections in the United States through emergency use authorization.
At the same time, it is necessary to continue to evaluate the safety and safety of these programs.
Effectiveness
.
S.
Drug Administration, said that with the continuous emergence of new mutant strains, it is critical to expand the available programs for the treatment of new crown infections in the United States through emergency use authorization.
At the same time, it is necessary to continue to evaluate the safety and safety of these programs.
Effectiveness
.
The U.
S.
Drug Administration approved the first oral drug that can be used urgently to treat new coronavirus infections on the 22nd
.
This oral drug is produced by Pfizer in the United States and can be used to treat adults and children 12 years of age and older suffering from mild to moderate COVID-19 , as well as people with a higher risk of severe illness
.
S.
Drug Administration approved the first oral drug that can be used urgently to treat new coronavirus infections on the 22nd
.
This oral drug is produced by Pfizer in the United States and can be used to treat adults and children 12 years of age and older suffering from mild to moderate COVID-19 , as well as people with a higher risk of severe illness
.
The US Food and Drug Administration approved the second oral drug that can be used urgently to treat new coronavirus infections on the 23rd
.
.
The U.
S.
Drug Administration said in a statement that the oral drug produced by Merck in the United States is called monabiravir, which is used to treat adults with mild to moderate new coronary disease and people with a higher risk of severe illness.
And people who cannot use other treatment programs approved by the US Drug Administration
.
S.
Drug Administration said in a statement that the oral drug produced by Merck in the United States is called monabiravir, which is used to treat adults with mild to moderate new coronary disease and people with a higher risk of severe illness.
And people who cannot use other treatment programs approved by the US Drug Administration
.
The statement said that monabigravir is a prescription drug, and patients must take it as soon as possible after the diagnosis of the new crown, and start taking it within 5 days after the appearance of the new crown symptoms, and the continuous use time cannot exceed 5 days
.
.
The statement said that monabiravir should not be used in people under the age of 18 because the drug may affect bone and cartilage growth
.
According to the results of animal reproduction studies, monabiravir is not recommended for women during pregnancy
.
Common side effects of this drug may include diarrhea, nausea, and dizziness
.
.
According to the results of animal reproduction studies, monabiravir is not recommended for women during pregnancy
.
Common side effects of this drug may include diarrhea, nausea, and dizziness
.
Cavazzoni, director of the Center for Drug Evaluation and Research of the U.
S.
Drug Administration, said that with the continuous emergence of new mutant strains, it is critical to expand the available programs for the treatment of new crown infections in the United States through emergency use authorization.
At the same time, it is necessary to continue to evaluate the safety and safety of these programs.
Effectiveness
.
S.
Drug Administration, said that with the continuous emergence of new mutant strains, it is critical to expand the available programs for the treatment of new crown infections in the United States through emergency use authorization.
At the same time, it is necessary to continue to evaluate the safety and safety of these programs.
Effectiveness
.
The U.
S.
Drug Administration approved the first oral drug that can be used urgently to treat new coronavirus infections on the 22nd
.
This oral drug is produced by Pfizer in the United States and can be used to treat adults and children 12 years of age and older suffering from mild to moderate COVID-19 , as well as people with a higher risk of severe illness
.
S.
Drug Administration approved the first oral drug that can be used urgently to treat new coronavirus infections on the 22nd
.
This oral drug is produced by Pfizer in the United States and can be used to treat adults and children 12 years of age and older suffering from mild to moderate COVID-19 , as well as people with a higher risk of severe illness
.
The US Food and Drug Administration approved the second oral drug that can be used urgently to treat new coronavirus infections on the 23rd
.
.
The U.
S.
Drug Administration said in a statement that the oral drug produced by Merck in the United States is called monabiravir, which is used to treat adults with mild to moderate new coronary disease and people with a higher risk of severe illness.
And people who cannot use other treatment programs approved by the US Drug Administration
.
S.
Drug Administration said in a statement that the oral drug produced by Merck in the United States is called monabiravir, which is used to treat adults with mild to moderate new coronary disease and people with a higher risk of severe illness.
And people who cannot use other treatment programs approved by the US Drug Administration
.
The statement said that monabigravir is a prescription drug, and patients must take it as soon as possible after the diagnosis of the new crown, and start taking it within 5 days after the appearance of the new crown symptoms, and the continuous use time cannot exceed 5 days
.
.
The statement said that monabiravir should not be used in people under the age of 18 because the drug may affect bone and cartilage growth
.
According to the results of animal reproduction studies, monabiravir is not recommended for women during pregnancy
.
Common side effects of this drug may include diarrhea, nausea, and dizziness
.
Female, female, female.
According to the results of animal reproduction studies, monabiravir is not recommended for women during pregnancy
.
Common side effects of this drug may include diarrhea, nausea, and dizziness
.
Cavazzoni, director of the Center for Drug Evaluation and Research of the U.
S.
Drug Administration, said that with the continuous emergence of new mutant strains, it is critical to expand the available programs for the treatment of new crown infections in the United States through emergency use authorization.
At the same time, it is necessary to continue to evaluate the safety and safety of these programs.
Effectiveness
.
S.
Drug Administration, said that with the continuous emergence of new mutant strains, it is critical to expand the available programs for the treatment of new crown infections in the United States through emergency use authorization.
At the same time, it is necessary to continue to evaluate the safety and safety of these programs.
Effectiveness
.
The U.
S.
Drug Administration approved the first oral drug that can be used urgently to treat new coronavirus infections on the 22nd
.
This oral drug is produced by Pfizer in the United States and can be used to treat adults and children 12 years of age and older suffering from mild to moderate COVID-19 , as well as people with a higher risk of severe illness
.
Child, child, kid S.
Drug Administration approved the first oral drug that can be used urgently to treat new coronavirus infections on the 22nd
.
This oral drug is produced by Pfizer in the United States and can be used to treat adults and children 12 years of age and older suffering from mild to moderate COVID-19 , as well as people with a higher risk of severe illness
.
